489 related articles for article (PubMed ID: 19740722)
1. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
Lee TW; Fedorak RN
Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
[TBL] [Abstract][Full Text] [Related]
5. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
6. Mucosal healing and anti TNFs in IBD.
van Assche G; Vermeire S; Rutgeerts P
Curr Drug Targets; 2010 Feb; 11(2):227-33. PubMed ID: 20210770
[TBL] [Abstract][Full Text] [Related]
7. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
9. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
10. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
Schreiber S
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
Williams CJ; Peyrin-Biroulet L; Ford AC
Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
[TBL] [Abstract][Full Text] [Related]
16. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
Bourne T; Fossati G; Nesbitt A
BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
[TBL] [Abstract][Full Text] [Related]
17. [Treatment with anti-TNFalpha agents in Crohn's disease: what drug we have to use and when?].
Gomollón F; López SG
Acta Gastroenterol Latinoam; 2008 Jun; 38(2):133-45. PubMed ID: 18697408
[TBL] [Abstract][Full Text] [Related]
18. [Main therapeutic advances in IBD in 2007].
Felley C; Mottet C; Maillard MH; Hess J; Delarive J; Michetti P
Rev Med Suisse; 2008 Jan; 4(141):200, 202-4, 206-8 passim. PubMed ID: 18335885
[TBL] [Abstract][Full Text] [Related]
19. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
Chang JT; Lichtenstein GR
Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
[TBL] [Abstract][Full Text] [Related]
20. Crohn's targeted therapy: myth or real goal?
Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K
Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
